A liquid biopsy is a blood draw (or, less commonly, a sample of another body fluid) used to detect fragments of DNA, intact cells, or tiny vesicles that tumors and other tissues shed into the bloodstream. Instead of cutting into a tumor with a needle or scalpel, clinicians can analyze what the tumor has already released on its own. The idea is not new; free-floating DNA in blood plasma was first documented in 1948.1Molecular Cancer Research. Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies But it took decades of advances in sequencing and molecular detection before that observation became a practical clinical tool. Today, liquid biopsies are reshaping cancer diagnosis, prenatal screening, and organ transplant monitoring, though the technology still has meaningful blind spots.
What Tumors Leave Behind in the Blood
Every living tissue sheds material into the bloodstream, and tumors are no exception. Three categories of tumor-derived material form the basis of most liquid biopsy tests.
The first and most widely used is cell-free DNA, or cfDNA. When cells die through normal turnover or through the chaotic death common inside fast-growing tumors, their DNA spills out and circulates in the plasma. The fraction that originates specifically from a tumor is called circulating tumor DNA, or ctDNA. These fragments are short, typically around 160 to 170 base pairs, and they carry the same mutations present in the tumor itself. The fragments come from several biological processes including programmed cell death, uncontrolled cell death, and active release, and they circulate in various structural forms such as nucleosomes and small particles.2PubMed Central. Origins, structures, and functions of circulating DNA in oncology In a person with cancer, ctDNA might represent anywhere from a tiny fraction of a percent to several percent of total cfDNA, depending on tumor size, location, and biology.
The second analyte is circulating tumor cells, or CTCs. These are whole cancer cells that have broken away from the primary tumor and entered the bloodstream. They are extremely rare, often just a handful among billions of normal blood cells, which makes capturing them technically demanding. But when they are found, they can be analyzed for surface proteins, gene expression, and internal mutations, providing a more complete biological portrait than DNA fragments alone.3PubMed Central. Circulating tumor cells: a window into cancer biology and metastasis
The third category is extracellular vesicles, especially exosomes. These are tiny membrane-bound packages that cells release to communicate with one another. Tumor-derived exosomes carry proteins, RNA, and DNA that reflect the biology of the parent cell. Research has shown they play roles in tumor growth, spread, and even drug resistance.4PubMed Central. The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction Because the vesicle membrane protects its cargo from degradation in the bloodstream, exosomes can be a more stable source of biomarkers than naked cfDNA. More broadly, the class of extracellular vesicles, which also includes microvesicles and apoptotic bodies, carries molecular cargo reflecting the state of the cells that released them, making them attractive targets for early cancer detection and prognosis.5Nano TransMed. Liquid biopsy based on EV biomarkers: A new frontier for early diagnosis and prognosis assessment of cancer at ESMO 2024 6PubMed Central. Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors
How the Signal Gets Read
Finding a handful of mutant DNA molecules among a much larger pool of normal DNA is the core engineering challenge of liquid biopsy. Several technologies have emerged to solve it, each with trade-offs in sensitivity, breadth, and cost.
Droplet digital PCR, or ddPCR, partitions a sample into thousands of tiny droplets, each containing at most one or two DNA molecules. Each droplet is then checked individually for a specific mutation. This approach is exquisitely sensitive for known mutations, but it can only look for targets you define in advance. Next-generation sequencing (NGS), by contrast, reads large stretches of DNA at once and can detect mutations across many genes simultaneously. In a head-to-head comparison in lung cancer patients, ddPCR and NGS agreed on the primary mutation status about 86% of the time, with even tighter agreement for a key resistance mutation.7PubMed. Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results In HPV-related head and neck cancers, both NGS and ddPCR significantly outperformed older quantitative PCR methods for detecting viral DNA in plasma, with sensitivities around 70% versus roughly 21% for quantitative PCR.8PubMed Central. Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer
Beyond just reading the DNA sequence, newer approaches examine how cfDNA is packaged and chemically modified. Methylation patterns, which are chemical tags on DNA that differ between tissues, can reveal where a fragment came from. Fragmentomics analyzes the sizes, end motifs, and distribution of cfDNA pieces across the genome to infer tissue of origin. A study combining methylation and fragmentation markers built a machine-learning model that distinguished esophageal cancer patients from healthy controls with 99% sensitivity and about 98% specificity.9PubMed Central. Cell-free DNA methylation and fragmentomics-based liquid biopsy for accurate esophageal cancer detection These physical and chemical features of cfDNA fragments, including fragment size and end patterns shaped by the nuclease content of their tissue of origin, add layers of information beyond the sequence itself.10PubMed. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies
Cancer Applications Already in the Clinic
Liquid biopsy has found its firmest footing in cancer care, where it serves several distinct roles.
The most established use is guiding treatment decisions. When a patient is diagnosed with advanced cancer, oncologists need to know which mutations are driving the disease so they can choose the right targeted therapy. A blood-based genomic profile can identify those actionable mutations without requiring a tissue biopsy, which is especially valuable when a tumor is hard to reach or when the patient is too sick for an invasive procedure.11PubMed Central. Liquid biopsy in cancer management: Integrating diagnostics and clinical applications 12PubMed. Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring In the United States, the FDA has approved several cfDNA-based companion diagnostic tests, most prominently for identifying EGFR mutations in non-small cell lung cancer.
A second role is tracking how tumors evolve during treatment. Cancers are genetically unstable, and new mutations conferring drug resistance can emerge within months of starting a targeted therapy. Sequencing ctDNA from repeated blood draws lets clinicians detect these resistance mutations, often months before imaging shows the cancer growing again.13Integrated Diagnostics. Unleashing the power of omics-driven liquid biopsy in anti-cancer drug resistance: From biomarker discovery to clinical translation This real-time monitoring opens the door to switching therapies earlier, before the resistant clone dominates.14PubMed Central. Liquid biopsy in cancer drug resistance: real-time monitoring, mechanistic insights, and translational applications
A third and increasingly important application is minimal residual disease, or MRD, detection. After surgery or chemotherapy, even if scans look clear, microscopic clusters of cancer cells can persist. Highly sensitive ctDNA assays can pick up these traces. In one study of head and neck cancer patients, a personalized ctDNA assay detected residual disease at levels as low as 0.0006% variant allele frequency, and in every case where the cancer eventually recurred, ctDNA was detectable months before clinical progression, with lead times ranging from roughly 3.5 to 8.5 months.15British Journal of Cancer. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) That kind of early warning could allow earlier intervention, though clinical trials are still working out whether acting on MRD results actually improves survival.
Multi-Cancer Early Detection
The most ambitious goal for liquid biopsy is screening apparently healthy people for cancer before symptoms appear. Multi-cancer early detection (MCED) tests aim to find signals from many different cancer types in a single blood draw and even predict which organ the cancer is in. This is harder than it sounds, because in early-stage disease the amount of ctDNA in the blood can be vanishingly small.
A multimodal approach that combines methylation and fragmentation data has shown promise. One large study using an ensemble machine-learning model that integrated eight different cfDNA features achieved an area under the curve of 0.95 in an independent validation cohort for distinguishing cancer patients from healthy controls.16eLife. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization Another multi-center validation of a test called OncoSeek reported about 58% overall sensitivity and 92% specificity, with the ability to detect 14 cancer types that account for roughly 72% of global cancer deaths. Sensitivity ranged from about 39% to 83% depending on the cancer type. For people who already had symptoms, the sensitivity climbed to about 73%.17PubMed Central. A large-scale, multi-centre validation study of an AI-empowered blood-based test for multi-cancer early detection
These numbers highlight a tension inherent in screening tests. At 58% sensitivity, the test misses more than four in ten cancers. At 92% specificity, roughly 8 out of 100 cancer-free people get a false alarm, which in a population-wide screening program could mean enormous numbers of unnecessary follow-up procedures. The field is still debating where the performance bar needs to be before population-level screening is justified, and regulators have not yet approved an MCED test for routine screening of average-risk adults.
Beyond Cancer
Liquid biopsy technology is not limited to oncology. Three non-cancer applications have gained substantial traction.
The most mature is non-invasive prenatal testing, or NIPT. A fetus sheds DNA into the mother’s bloodstream through the placenta, and by analyzing that fetal cfDNA, clinicians can screen for chromosomal conditions. A large meta-analysis of 117 studies found that cfDNA-based testing had a sensitivity above 99% for fetal sex determination and Rh blood type, making it essentially diagnostic for those purposes. For Down syndrome, sensitivity was about 99.4% with specificity above 99.9%. Performance was somewhat lower for other chromosomal conditions like trisomy 18 and monosomy X.18PubMed. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis NIPT has rapidly become a standard part of prenatal care in many countries, substantially reducing the need for amniocentesis.
Organ transplant monitoring is another growing area. When a transplanted organ is being rejected, its cells die at higher rates and release donor-derived cfDNA into the recipient’s blood. Measuring that donor fraction can flag rejection earlier than traditional monitoring approaches. A study in kidney transplant recipients found that donor-derived cfDNA levels were strongly associated with all types of rejection, and adding the cfDNA measurement to standard monitoring improved the ability to predict rejection events.19Nature Medicine. Cell-free DNA for the detection of kidney allograft rejection The approach has robust clinical evidence supporting its use for monitoring graft health across multiple organ types.20PubMed Central. Donor-derived cell-free DNA as a diagnostic tool in transplantation
A third frontier is infectious disease. Instead of waiting days for traditional blood cultures to grow bacteria, sequencing microbial cfDNA in plasma can identify pathogens directly. In ICU patients with sepsis, microbial cfDNA sequencing outperformed blood culture for certain hospital-acquired bacteria and was the only method that detected DNA viruses.21PubMed Central. Plasma Microbial Cell-Free DNA Sequencing Technology for the Diagnosis of Sepsis in the ICU In newborns, where sepsis is life-threatening and blood volumes are tiny, sequencing has identified infections that cultures missed entirely.22Pediatric Research. Microbial cell-free DNA-sequencing as an addition to conventional diagnostics in neonatal sepsis
What Can Go Wrong With the Results
Liquid biopsy tests are powerful, but they are not immune to false signals. The most important confounder is clonal hematopoiesis, a process in which blood-forming stem cells acquire mutations and gradually expand over time. This happens naturally with aging and does not mean a person has cancer. But when a liquid biopsy detects one of these mutations in cfDNA, it can be mistaken for a tumor-derived signal. Misclassifying a clonal hematopoiesis mutation as a cancer mutation could lead to unnecessary workups or inappropriate treatment decisions.23PubMed Central. Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications 24Clinical Cancer Research. Clonal Hematopoiesis: A New Layer in the Liquid Biopsy Story in Lung Cancer Modern assays are increasingly designed to filter out this “biological noise,” often by simultaneously sequencing white blood cells to identify which mutations come from the blood rather than the tumor.
Sample handling also matters more than you might expect. Cell-free DNA in blood is fragile, and if white blood cells in the sample break open during storage and transport, they release large amounts of normal genomic DNA that dilutes and obscures the tumor signal. Standard EDTA blood collection tubes, which work fine for most lab tests, allow cfDNA concentrations to spike by 10- to 20-fold after a few days at room temperature as cells lyse.25PubMed. Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma Specialized stabilizing tubes preserve the sample for days to weeks, making it possible to ship blood to centralized testing labs without the signal degrading.26PubMed Central. Comparison of Roche Cell-Free DNA Collection Tubes to Streck Cell-Free DNA BCTs for sample stability using healthy volunteers It sounds mundane, but the wrong tube or a delayed shipment can turn a valid test into a useless one.
Cost and Access
A single liquid biopsy test typically costs anywhere from a few hundred to several thousand dollars depending on how comprehensive the genomic panel is. Whether that represents good value depends heavily on context. A systematic review of health economic studies found that liquid biopsy was cost-effective in 75% of the analyses examined, spanning screening, treatment selection, and monitoring. Budget impact was generally modest or even cost-saving in most analyses.27PubMed Central. Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review
The picture gets murkier for screening. A modeling study of liquid biopsy for colorectal cancer screening in previously unscreened individuals found that while the test caught more cancers at an early stage, it was not cost-effective under standard willingness-to-pay thresholds when compared to colonoscopy alone.28JAMA Network Open. Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened A separate analysis from Brazil reached a similar conclusion for lung cancer screening, finding that liquid biopsy screening in high-risk individuals produced only a modest gain in quality-adjusted life years at a cost that far exceeded Brazilian cost-effectiveness thresholds.29PLoS One. Cost-effectiveness assessment of liquid biopsy for early detection of lung cancer in Brazil This does not mean screening liquid biopsies will never make economic sense. Costs tend to fall rapidly as technologies mature, and if test performance improves, the calculus shifts. But for now, the strongest economic case is in guiding treatment for patients who already have a diagnosis, where the alternative might be a riskier, more expensive tissue biopsy or trial-and-error prescribing.
Where Things Are Headed
The research frontier involves combining multiple data layers rather than relying on any single biomarker. Instead of analyzing just mutations in ctDNA, next-generation tests integrate methylation patterns, fragment sizes, protein markers, and sometimes RNA or metabolomic data from extracellular vesicles into a single readout. Pairing that multi-omic data with artificial intelligence is increasingly seen as the path to high-accuracy early detection.30Intelligent Oncology. Integrating multi-omic liquid biopsies and artificial intelligence: The next frontier in early cancer detection
The optimism is warranted but tempered by reality. A scoping review covering 115 studies on AI and multi-omics in liquid biopsy for genitourinary cancers found that while sophisticated fusion models offered advantages over simpler approaches, most studies were hampered by small sample sizes, batch effects from different labs and platforms, and a lack of independent external validation.31PubMed. Artificial intelligence and multi-omics integration in liquid biopsy for genitourinary cancers: a systematic scoping review In other words, the models look promising in the datasets they were built on, but proving they work reliably across diverse populations and clinical settings is a separate and harder challenge. Prospective randomized trials testing whether MCED screening actually reduces cancer deaths are now underway in several countries, and their results over the next few years will largely determine how quickly blood-based cancer screening moves from research curiosity to routine medical practice.